Astria Therapeutics Overview
- Year Founded
-
2008
- Status
-
Public
- Employees
-
78
- Stock Symbol
-
ATXS
- Investments
-
1
- Share Price
-
$4.04
- (As of Thursday Closing)
Astria Therapeutics General Information
Description
Astria Therapeutics Inc is a biopharmaceutical company engaged to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Its program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema. Their second product candidate is STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, or AD, an immune disorder associated with loss of skin barrier function and itching.
Contact Information
Website
www.astriatx.comCorporate Office
- 75 State Street
- Suite 1400
- Boston, MA 02109
- United States
Corporate Office
- 75 State Street
- Suite 1400
- Boston, MA 02109
- United States
Astria Therapeutics Timeline
Astria Therapeutics Stock Performance
As of 17-Apr-2025, Astria Therapeutics’s stock price is $4.04. Its current market cap is $228M with 56.4M shares.
(As of Thursday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $4.04 | $3.98 | $3.56 - $12.92 | $228M | 56.4M | 288K | -$1.68 |
Astria Therapeutics Financials Summary
As of 31-Dec-2024, Astria Therapeutics has a trailing 12-month revenue of null.
|
In Thousands, USD |
TTM 31-Dec-2024 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 | FY 2022 31-Dec-2022 |
|---|---|---|---|---|
| EV | 261,201 | 261,201 | 222,153 | 390,332 |
| Revenue | 0 | 0 | 0 | 0 |
| EBITDA | (111,620) | (111,620) | (83,092) | (53,558) |
| Net Income | (94,260) | (94,260) | (72,891) | (51,834) |
| Total Assets | 342,363 | 342,363 | 254,666 | 230,633 |
| Total Debt | 5,353 | 5,353 | 329 | 939 |
Astria Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Astria Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
Astria Therapeutics Comparisons
Industry
Financing
Details
Astria Therapeutics Competitors (90)
One of Astria Therapeutics’s 90 competitors is NGM Biopharmaceuticals, a Private Equity-Backed company based in South San Francisco, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| NGM Biopharmaceuticals | Private Equity-Backed | South San Francisco, CA | ||||
| Dyne Therapeutics | Formerly VC-backed | Waltham, MA | ||||
| Rallybio | Formerly VC-backed | New Haven, CT | ||||
| NexImmune | Formerly VC-backed | Gaithersburg, MD | ||||
| Kite Pharma | Formerly VC-backed | Santa Monica, CA |
Astria Therapeutics Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Astria Therapeutics Patents
Astria Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20240343829-A1 | Anti-plasma kallikrein antibody dosing regimens for treating hereditary angioedema | Pending | 13-Dec-2022 | ||
| CA-3208312-A1 | Plasma kallikrein antibodies and uses thereof | Pending | 28-Jan-2021 | ||
| AU-2022214914-A1 | Plasma kallikrein antibodies and uses thereof | Pending | 28-Jan-2021 | ||
| EP-4284839-A1 | Plasma kallikrein antibodies and uses thereof | Pending | 28-Jan-2021 | ||
| US-20240218079-A1 | Plasma kallikrein antibodies and uses thereof | Pending | 28-Jan-2021 | C07K16/40 |
Astria Therapeutics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Astria Therapeutics Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Astria Therapeutics Acquisitions (1)
Astria Therapeutics’s most recent deal was a Merger/Acquisition with Quellis Biosciences. The deal was made on 28-Jan-2021.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Quellis Biosciences | 28-Jan-2021 | Merger/Acquisition | Drug Discovery |
Astria Therapeutics ESG
Risk Overview
Risk Rating
Updated December, 11, 2023
28.31 | Med Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 15,109
Rank
Percentile
Pharmaceuticals
Industry
of 861
Rank
Percentile
Biotechnology
Subindustry
of 371
Rank
Percentile
Astria Therapeutics FAQs
-
When was Astria Therapeutics founded?
Astria Therapeutics was founded in 2008.
-
Where is Astria Therapeutics headquartered?
Astria Therapeutics is headquartered in Boston, MA.
-
What is the size of Astria Therapeutics?
Astria Therapeutics has 78 total employees.
-
What industry is Astria Therapeutics in?
Astria Therapeutics’s primary industry is Drug Discovery.
-
Is Astria Therapeutics a private or public company?
Astria Therapeutics is a Public company.
-
What is Astria Therapeutics’s stock symbol?
The ticker symbol for Astria Therapeutics is ATXS.
-
What is the current stock price of Astria Therapeutics?
As of 17-Apr-2025 the stock price of Astria Therapeutics is $4.04.
-
What is the current market cap of Astria Therapeutics?
The current market capitalization of Astria Therapeutics is $228M.
-
Who are Astria Therapeutics’s competitors?
NGM Biopharmaceuticals, Dyne Therapeutics, Rallybio, NexImmune, and Kite Pharma are some of the 90 competitors of Astria Therapeutics.
-
What is Astria Therapeutics’s annual earnings per share (EPS)?
Astria Therapeutics’s EPS for 12 months was -$1.68.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
